ETF Performance Report October

On the other hand, the worst non-leveraged ETPs of the past month include the BioShares Biotechnology Clinical Trials Fund (NasdaqGM: BBC) down 19.9%, Loncar Cancer Immunotheraphy ETF (NasdaqGM: CNCR) down 18.4% and ALPS Medical Breakthroughs ETF (NYSEArca: SBIO) down 16.4%.


The month of October started off on a positive note with strong economic data from the manufacturing sector, lower jobless claims and steady employment numbers. However, global markets remained muted on speculation the European Central Bank would begin tapering its quantitative easing program.

The equities market began to weaken mid-October after stronger economic news fueled bets that the Federal Reserve would begin cutting interest rates as soon as December.

Overall, October was stuck in sideways trading with positive earnings reports and signs of economic strength buoying markets.

Nevertheless, markets dropped off toward the end of the month after the FBI said it was looking into additional emails related to Hillary Clinton, which lowered the outlook of a Clinton presidency and added to greater equity volatility fueled by political risk from a Donald Trump administration.

For more information on ETFs, visit our ETF Performance Reports category.